De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Blonder Tongue Laboratories Balans Gezondheid

Financiële gezondheid criteriumcontroles 0/6

Onvoldoende gegevens om de gezondheid van Blonder Tongue Laboratories te bepalen

Belangrijke informatie

n/a

Verhouding schuld/eigen vermogen

n/a

Schuld

Rente dekkingsratio	n/a
Contant	n/a
Aandelen	n/a
Totaal verplichtingen	n/a
Totaal activa	n/a

Recente financiële gezondheidsupdates

Recent updates

Have Blonder Tongue Laboratories, Inc. (NYSEMKT:BDR) Insiders Been Selling Their Stock?

Dec 23

Analyse van de financiële positie

Kortlopende schulden: Er zijn onvoldoende gegevens om te bepalen of de kortetermijnactiva van BDRL de kortetermijnschulden dekken.

Langlopende schulden: Er zijn onvoldoende gegevens om te bepalen of de kortetermijnactiva van BDRL de langetermijnschulden dekken.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: Er zijn onvoldoende gegevens om de netto schuld/eigen vermogen ratio BDRL te berekenen om te bepalen of deze voldoende is.

Schuld verminderen: Er zijn onvoldoende gegevens om te bepalen of de schuld/eigen vermogen-ratio van BDRL de afgelopen 5 jaar is gedaald.

Schuldendekking: Er zijn onvoldoende gegevens om te bepalen of de schulden van BDRL goed gedekt zijn door de operationele kasstroom.

Rentedekking: Er zijn onvoldoende gegevens om te bepalen of de rentebetalingen van BDRL op haar schulden goed worden gedekt door EBIT.

Blonder Tongue Laboratories Balans Gezondheid

Financiële gezondheid criteriumcontroles 0/6

Belangrijke informatie

Recente financiële gezondheidsupdates

NYSE American to Suspend Trading Immediately in Blonder Tongue Laboratories

NYSE American to Commence Delisting Proceedings Against Blonder Tongue Laboratories

Blonder Tongue Laboratories Receives Non-Compliance Letter from NYSE American

NYSE Accepts Compliance Plan of Blonder Tongue Laboratories, Inc

Recent updates

Blonder Tongue Announces IP Failover Feature Added to NXG Video Delivery System

Blonder Tongue Laboratories, Inc. Announces the Retirement of Stephen K. Necessary from the Board

Blonder Tongue Laboratories, Inc. Announces President Changes

Blonder Tongue Laboratories, Inc. to Report Q3, 2022 Results on Nov 04, 2022

Blonder Tongue Laboratories Announces Product Standardization with Tier One Broadband Cable Operator

Blonder Tongue Laboratories, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Blonder Tongue Laboratories, Inc.(OTCPK:BDRL) dropped from S&P TMI Index

NYSE American to Suspend Trading Immediately in Blonder Tongue Laboratories

Blonder Tongue Laboratories, Inc. Announces Furloughing Ronald V. Alterio, the Senior Vice President-Engineering and Chief Technology Officer

Blonder Tongue Laboratories, Inc. Announces Resignation of Anthony Bruno as BOD, Effective from May 25, 2022

Blonder Tongue Laboratories, Inc., Annual General Meeting, May 25, 2022

Blonder Tongue Laboratories, Inc. Announces Retirement of James H. Williams as Member of the Board of Director

NYSE American to Commence Delisting Proceedings Against Blonder Tongue Laboratories

Independent Director Rick Briggs has left the company

Independent Director recently sold US$102k worth of stock

Third quarter 2021 earnings released: US$0.016 loss per share (vs US$0.18 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS US$0.14 (vs US$0.12 loss in 2Q 2020)

Director recently sold US$74k worth of stock

First quarter 2021 earnings released: US$0.036 loss per share (vs US$0.21 loss in 1Q 2020)

Full year 2020 earnings released: US$0.76 loss per share (vs US$0.077 loss in FY 2019)

Independent Director recently sold US$77k worth of stock

Blonder Tongue Laboratories, Inc. announced that it has received $0.6 million in funding

New 90-day high: US$1.85

MD of Strategic Accounts & Director recently sold US$52k worth of stock

Have Blonder Tongue Laboratories, Inc. (NYSEMKT:BDR) Insiders Been Selling Their Stock?

Blonder Tongue Laboratories Receives Non-Compliance Letter from NYSE American

New 90-day high: US$1.75

Third quarter 2020 earnings released: US$0.18 loss per share

New 90-day high: US$1.50

NYSE Accepts Compliance Plan of Blonder Tongue Laboratories, Inc

New 90-day high - US$1.35

Earnings released

Blonder Tongue Laboratories, Inc. to Report Q2, 2020 Results on Aug 07, 2020

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven